The 15q25.1 Regulatory Variant: A Second Lever on Nicotine Dependence and Lung Cancer Risk
On chromosome 15, a busy stretch of DNA called 15q25.1 houses a cluster of nicotinic acetylcholine receptor genes — CHRNA5, CHRNA3, and CHRNB4 — plus several neighboring genes including AGPHD1 (also known as HYKK, hydroxylysine kinase). The rs8034191 variant sits in the third intron of AGPHD1, just upstream of the CHRNA3 gene that codes for the alpha-3 nicotinic receptor subunit. This locus has been among the most replicated findings in lung cancer and nicotine dependence genomics | Multiple GWAS identified chromosome 15q25 variants at p-values below 10⁻¹⁸ for lung cancer, and rs8034191 is one of two key tagging variants at this region — the other being rs1051730 in CHRNA3, which is already covered in GeneOps.
Although rs8034191 and rs1051730 are in high linkage disequilibrium (r²=0.91 in Europeans), they are not identical and are partially independent in non-European populations. Understanding rs8034191 adds meaningful information for people of African or Asian ancestry, where the LD structure differs, and helps characterize the regulatory — rather than coding — mechanisms at this locus.
The Mechanism
Unlike rs1051730, which is a synonymous coding change in CHRNA3, rs8034191 is a non-coding intronic variant. Its functional impact operates through gene regulation: rs8034191 acts as a lung cis- and trans-eQTL | Expression quantitative trait loci alter how much mRNA a gene produces in specific tissues, influencing the expression of multiple nearby genes including CHRNA3, CHRNA5, HYKK, IREB2, and PSMA4 in lung tissue. The C allele is associated with altered expression of these genes independently of smoking status, meaning the regulatory effect is present regardless of tobacco exposure.
The variant also influences [DNA methylation patterns | Epigenetic modification of cytosine bases that silences or activates gene regions] at the IREB2, CHRNA3, and PSMA4 promoters, independently of smoking. IREB2 encodes iron-regulatory protein 2 and has been implicated in COPD pathogenesis. The combined eQTL and methylation effects suggest rs8034191 reshapes the entire transcriptional landscape of this genomic neighborhood.
Approximately 30% of the variant's effect on COPD development is mediated through smoking behavior (pack-years), while the remaining effect is direct — acting through the gene expression changes described above. This distinguishes rs8034191 from a purely behavioral risk factor.
The Evidence
A 14-study meta-analysis | Covering 14,075 cases and 12,873 controls from published case-control studies found that the C allele confers OR=1.23 (95% CI: 1.08–1.40; P=0.002) for lung cancer under the allelic model. The effect is strongest in Caucasians (OR=1.22) and African Americans (OR=1.39) and absent in East Asians, where the C allele is rare (frequency ~3%).
A separate 13-study meta-analysis | Testing three genetic models — dominant, additive, and recessive confirmed significant associations across all three models: dominant OR=1.34 (95% CI: 1.29–1.41), additive OR=1.61 (95% CI: 1.50–1.73), and recessive OR=1.41 (95% CI: 1.32–1.50). The recessive model finding — indicating that two copies of the C allele confer a disproportionate effect — is a distinctive feature of rs8034191 compared to rs1051730.
For COPD, a genome-wide association study of COPD | Bergen et al., PLOS Genetics 2009, including subjects from multiple cohorts found rs8034191 significantly associated with COPD (OR=1.29, 95% CI: 1.18–1.41), with the population attributable risk of the C allele estimated at 12.2% for COPD in the general population and 14.3% in current smokers. An independent mediation analysis found that 30% of the COPD effect is mediated by smoking behavior | Measured as pack-years in path analysis models, meaning 70% operates through direct biological mechanisms.
For smoking behavior, a Canadian cohort study | 526 women in Northeastern Ontario found that women carrying the CC genotype had a 2.8-fold increased odds of being heavy smokers (>20 cigarettes/day) after adjusting for age, confirming the variant's strong influence on smoking quantity independent of other factors. The variant is also associated with nicotine and opioid dependence severity, demonstrating a pleiotropic role across addictive substances | The same nicotinic receptor locus influences dependence on multiple drugs via overlapping neural circuits.
Practical Implications
If you carry one or two copies of the C allele, your baseline risk for heavy nicotine dependence and lung disease is elevated through both behavioral and biological pathways. The behavioral pathway: C allele carriers experience altered nicotinic receptor activity, making them more vulnerable to progressing from occasional to heavy smoking. The biological pathway: even independent of smoking, the eQTL effects on CHRNA3 and IREB2 expression appear to influence lung tissue susceptibility.
For smokers, the priority is cessation — the evidence consistently shows that quitting reduces lung cancer and COPD risk substantially regardless of genotype. For CC carriers who have never smoked, the direct biological effect (30% of the COPD risk) is still present but substantially lower in absolute terms than for smokers. Lung function monitoring is warranted for CC smokers, particularly spirometry to detect early obstructive patterns.
The variant is particularly relevant for people of African ancestry, where the LD structure between rs8034191 and rs1051730 is weaker, and the two variants provide partially independent information about risk.
Interactions
rs8034191 is in strong linkage disequilibrium with rs1051730 in CHRNA3 (r²=0.91 in Europeans), meaning most Europeans with the C allele also carry the rs1051730-A allele. In non-European populations, particularly African Americans, this correlation is weaker, making rs8034191 and rs1051730 partially independent risk indicators. The locus also contains rs16969968 in CHRNA5, which encodes the functionally impactful Asp398Asn amino acid change — rs16969968 is the strongest single functional variant at this locus, while rs8034191 captures primarily regulatory effects.
The three variants can be considered a risk haplotype: individuals who carry risk alleles at all three (rs16969968-A, rs1051730-A, rs8034191-C) are at substantially higher cumulative risk for nicotine dependence, lung cancer, and COPD than those carrying any single risk allele alone, though no published compound-genotype analyses exist to precisely quantify the triple-carrier odds ratio.
All Genotypes
No elevated genetic risk from this 15q25.1 variant
You carry two copies of the reference T allele at rs8034191, meaning this particular regulatory variant does not add to your genetic risk for heavy smoking or lung cancer. About 40% of Europeans share this genotype. The 15q25.1 locus contains additional coding and regulatory variants in CHRNA3 and CHRNA5 that can independently affect risk and may be assessed separately.
Moderately elevated risk for heavy smoking and lung cancer via 15q25.1 regulation
You carry one copy of the C risk allele at rs8034191. About 47% of Europeans share this genotype, making it the most common at this locus. The C allele alters expression of nicotinic receptor genes (CHRNA3, CHRNA5) and the iron-regulatory gene IREB2 in lung tissue, increasing susceptibility to heavy smoking and lung disease. Meta-analyses report approximately 20–23% elevated lung cancer risk per C allele in Europeans and African Americans. Your COPD risk is also modestly elevated — this variant accounts for roughly 12% of population-level COPD risk when present.
Substantially elevated risk for heavy smoking, COPD, and lung cancer
You carry two copies of the C risk allele at rs8034191. About 14% of Europeans share this genotype. Meta-analyses show the CC genotype is associated with a 41% higher lung cancer risk under the recessive model (OR=1.41), and a Canadian cohort found CC women had 2.8 times the odds of being heavy smokers compared to TT carriers. Your COPD risk is elevated through both a behavioral pathway (increased nicotine dependence, leading to heavier smoking) and a direct biological pathway (altered CHRNA3, IREB2, and PSMA4 expression in lung tissue). Approximately 30% of the COPD risk operates even without smoking exposure.